Persistent Intraocular Residue with the Use of Dexycu® in Cataract Extraction: A Case Series

Ryan T. Wallace a, Annika M. Hansen b, John A. Musser VI a, Anthony P. Mai a and Craig J. Chaya a

a John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA. 
b School of Medicine, University of Utah, Salt Lake City, UT, USA.

Authors’ contributions

This work was carried out in collaboration among all authors. Author RTW performed the statistical analysis, wrote the protocol, managed the analyses of the study, and assisted with manuscript drafting. Author AMH managed the analyses of the study and assisted with manuscript drafting. Author JAMVI managed the analyses of the study and assisted with manuscript drafting and revision. Author APM managed the analyses of the study and assisted with manuscript drafting. Author CJC designed the study. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/OR/2022/v17i330258

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/91015

Original Research Article

ABSTRACT

Purpose: The objective of this article is to report 8 cases of persistent IOL residue associated with the use of Dexycu® in the context of cataract surgery and then to subsequently describe each patient’s clinical course.

Observations and Presentation: Between 2020-2021, persistent residue was noted in 8 eyes of 7 patients who received Dexycu® implants after cataract surgery. The residue was identified an average of 1.63 months after surgery (range 0.20-4.23). A subsequent procedure removed the residue from the intraocular lens; the average time to the follow-up procedure after surgery was 4.71 months (range 1.90-11.20).

Conclusions and Importance: The Bausch and Lomb intraocular lenses seem to be predisposed to a Dexycu® persistent opacification, however correlation does not equate with causation. This article documents cases of persistent IOL residue with the use of Dexycu® and the MX60 lenses and its toric varieties. Further evaluation is necessary to elucidate the mechanism and risk factors for this occurrence.

*Corresponding author: E-mail: Craig.Chaya@hsc.utah.edu;
Keywords: Cataract surgery; Dexycu; residue polish; tano diamond brush.

1. INTRODUCTION

Almost 28 million cataract surgeries are performed worldwide each year [1]. Efforts to improve the patient experience and surgical outcomes by targeting postoperative inflammation have yielded several methods that do not require use of postoperative eye drops. Dexycu® (Eyepoint Pharmaceuticals, Inc. Watertown, MA) is a novel posterior chamber dexamethasone drug delivery suspension that has been shown to effectively control postoperative inflammation in patients for up to 21 days after cataract surgery [2]. A single vial of Dexycu® suspension is equivalent to 51.7 mg of dexamethasone suspended in a Verisome® acetyl triethyl citrate spherule (Eyepoint Pharmaceuticals, Inc. Watertown, MA) [2].

Dexycu® was approved by the FDA in 2018. Possible adverse reactions listed by the FDA include increased intraocular pressure, corneal edema, and iritis [3]. Since the approval of Dexycu®, other complications have been reported such as iris atrophy [4]. However, intraocular lens (IOL) residue associated with the use of Dexycu® is not well studied. The objective of this article is to present a series of 8 patients who had phacoemulsification with intraocular lens implantation and subsequently developed persistent IOL residue associated with the use of Dexycu®.

2. CASE SERIES DESCRIPTION

Patient 1: 61 year old female with a relevant past medical history of Type 2 diabetes mellitus (A1C: 6.0), essential hypertension, meibomian gland dysfunction / dry eye syndrome, poor tear film OU (TBUT: 3 seconds), and 2+ nuclear senile cataracts OU. This patient underwent right eye phacoemulsification with intraocular lens implantation (MX60E, Bausch + Lomb, Laval, Canada) and notably on post-op day 1 had a deep anterior chamber with 2+ cell. At a follow-up exam, 1.63 months later, there was residue noted on the inferior anterior surface of the right intraocular lens.

Residue Recognition Clinical Examination:

After 2.93 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

Two paracentesis incisions were made with a 1 mm diamond blade. Lidocaine MPF was injected into the anterior chamber followed by DiscoVisc® (Alcon Inc., Geneva, Switzerland). The 23g Tano diamond brush (Synergetics Inc., O’Fallon, MO, US) was then used to gently polish the residue from the anterior surface of the intraocular lens. Once it was free, bimanual irrigation/aspiration was used to remove the viscoelastic and residue from the anterior chamber. Vigamox was injected into the anterior chamber at the end of the case. The wounds were inspected and found to be watertight after hydration. Topical Betadine, Brimonidine, and antibiotic drops were placed on the corneal surface.
The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.

Post-Procedure Clinical Examination at 1 Week:

Patient 2: 65 year old male with a relevant past medical history of severe stage primary open angle glaucoma and combined forms of age-related cataract in both eyes. This patient underwent left eye phacoemulsification with intraocular lens implantation (MX60UT, Bausch + Lomb, Laval, Canada), ab-interno iTrack catheter and viscoelastic canaloaplasty, along with Hydrus microstent insertion. At a follow-up exam, 4.23 months later, there was diffuse posterior capsular opacification bilaterally and the patient reported he felt like he was “looking through frosted glass”.

Residue Recognition Clinical Examination:
The patient has not undergone a re-operation to date, but is continuing to be monitored.

**Patient 3**: 76 year old male with a relevant past medical history of intermediate stage primary angle closure of the left eye, anatomical narrow angle borderline glaucoma of right eye, and combined forms of age-related cataracts in both eyes. This patient underwent phacoemulsification with intraocular lens implantation (MX60E, Bausch + Lomb, Laval, Canada), gonirosynechiolysis, and goniotomy in the left eye and a week later phacoemulsification with intraocular lens implantation (AMO Tecnis ZCB00, Johnson & Johnson, New Brunswick, NJ) in the right eye. At a follow-up exam, 0.2 months later, there was residue noted on the anterior surface of the left intraocular lens and the right inferior iris.

**Residue Recognition Clinical Examination:**

<table>
<thead>
<tr>
<th>Visual Acuity (Snellen - Linear)</th>
<th>Neuro/Psych</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Right</strong></td>
<td><strong>Left</strong></td>
</tr>
<tr>
<td>Dist sc</td>
<td>20/20</td>
</tr>
<tr>
<td><strong>Tonometry</strong> (iCare, 11:26 AM)</td>
<td></td>
</tr>
<tr>
<td><strong>Right</strong></td>
<td><strong>Left</strong></td>
</tr>
<tr>
<td>Pressure</td>
<td>13</td>
</tr>
</tbody>
</table>

After 5.27 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

A 1-mm clear corneal paracentesis incision was created inferiorly through which lidocaine with epinephrine was injected into the anterior chamber. Viscoelastic (DiscoVisc®, Alcon Inc., Geneva, Switzerland) was used to stabilize the anterior chamber. Two additional 1 mm clear corneal paracentesis incisions were made superiorly. A Tano scrubber (Synergetics Inc., O’Fallon, MO, US) was used to gently scrape residue off the intraocular lens implant and polish the lens. Bimannual irrigation/aspiration was used to extract the viscoelastic from the anterior chamber. The corneal wound edges were hydrated with balanced salt solution on a cannula. Then, 0.1 ml of Vigamox was injected into the anterior chamber. The wounds were inspected and were found to be watertight. Topical Betadine, Alphagan P, and antibiotic drops were placed on the corneal surface.

The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.

**Post-Procedure Clinical Examination at 1 Week:**

<table>
<thead>
<tr>
<th>Visual Acuity (Snellen - Linear)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Right</strong></td>
<td><strong>Left</strong></td>
</tr>
<tr>
<td>Dist sc</td>
<td>20/20</td>
</tr>
<tr>
<td><strong>Tonometry</strong> (Applanation, 2:51 PM)</td>
<td></td>
</tr>
<tr>
<td><strong>Right</strong></td>
<td><strong>Left</strong></td>
</tr>
<tr>
<td>Pressure</td>
<td>14</td>
</tr>
</tbody>
</table>
Patient 4: A 79-year-old female with a relevant past medical history of essential hypertension, severe stage primary open angle glaucoma, blepharitis/meibomian gland dysfunction, and combined forms of age-related cataract of both eyes. Previous ocular surgeries included bilateral trabeculectomy with mitomycin c. This patient underwent left eye phacoemulsification with intraocular lens insertion (Toric MX60UET200, Bausch + Lomb, Laval, Canada). Two weeks later the patient underwent right eye phacoemulsification with intraocular lens insertion (Toric MX60UET350, Bausch + Lomb, Laval, Canada). At a follow-up exam, 3.9 months later, there was residue noted on the anterior surface of the right intraocular lens.

Residue Recognition Clinical Examination:

<table>
<thead>
<tr>
<th>Slit Lamp Exam</th>
<th>Right</th>
<th>Left</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctiva/Sclera</td>
<td>White and quiet</td>
<td>White and quiet</td>
</tr>
<tr>
<td>Cornea</td>
<td>Clear</td>
<td>Clear</td>
</tr>
<tr>
<td>Anterior Chamber</td>
<td>Deep and quiet</td>
<td>Deep and quiet</td>
</tr>
<tr>
<td>Iris</td>
<td>normal</td>
<td>normal</td>
</tr>
<tr>
<td>Lens</td>
<td>PC IOL, clear s/p removal of IOL deposits</td>
<td>PC IOL, clear s/p removal of IOL deposits</td>
</tr>
</tbody>
</table>

After 4.37 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

Two 1-mm clear corneal paracentesis incisions were created through which lidocaine with epinephrine was injected into the anterior chamber. Viscoelastic (DiscoVisc®, Alcon Inc., Geneva, Switzerland) was used to stabilize the anterior chamber. A Tano diamond dusted scraper (Synergetics Inc., O’Fallon, MO, US) was used to polish away the Dexycu® residue. The corneal wound edges were hydrated with balanced salt solution on a cannula and the bimanual irrigation/aspiration handpiece was used to extract the remaining viscoelastic. Then, 0.1 ml of Vigamox was injected into the anterior chamber. The wounds were checked and found to be water tight.

The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.
Post-Procedural Clinical Examination at 6 Weeks:

Patient 5: 53 year old male with a relevant past medical history of chronic left eye uveitis, essential hypertension, type 2 diabetes mellitus, posterior synechiae in the right eye, and nuclear senile cataract in both eyes. This patient underwent phacoemulsification with intraocular lens implantation (MX60E, Bausch + Lomb, Laval, Canada) along with posterior synechialysis in the right eye. Two weeks later the patient had phacoemulsification with intraocular lens implantation (MX60E, Bausch + Lomb, Laval, Canada) of the left eye. At a follow-up exam, 0.2 months post-op, there was residue noted in the right eye at the inferior portion of the anterior chamber.

Right Eye Residue Recognition Clinical Examination:

At a follow-up exam, 0.77 months post-op there was residue noted at the anterior surface of the left intraocular lens.

Left Eye Residue Recognition Clinical Examination:
After 1.9 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

A 1 mm clear corneal paracentesis incision was created through which lidocaine with epinephrine was injected into the anterior chamber. Another paracentesis was made superiorly. Viscoelastic (DiscoVisc®, Alcon Inc., Geneva, Switzerland) was used to stabilize the anterior chamber. As viscoelastic was injected the residue overlying the lens began to peel away. A retina ILM forceps was then used to peel off the residue. A Tano retina polisher (Synergetics Inc., O’Fallon, MO, US) was used to remove remaining residue. The lens was inspected and noted to be clean without any scratches or defects. The remaining viscoelastic was aspirated with bimanual I&A. The corneal wound edges were hydrated with balanced salt solution on a cannula and the irrigation/aspiration handpiece was used to extract the remaining viscoelastic. The wounds were inspected and were found to be watertight. 0.1 ml of Moxifloxacin was injected. ReSure corneal glue was placed over the incisions. Topical Betadine, Brimonidine, and antibiotic drops were placed on the corneal surface.

The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.
Patient 6: 66 year old female with a relevant past medical history of combined forms of essential hypertension, blepharitis, conjunctivochalasis, and age-related cataracts in both eyes. Previous ocular surgeries include LASIK in both eyes. This patient underwent left eye phacoemulsification with intraocular lens insertion (MX60E, Bausch + Lomb, Laval, Canada). At a follow-up exam, 0.8 months post-op there was residue noted at the anterior surface of the left intraocular lens.

Residue Recognition Clinical Examination Day Left Eye:

<table>
<thead>
<tr>
<th>Visual Acuity (Snellen - Linear)</th>
<th>Pupils</th>
<th>APD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right:</td>
<td>Left:</td>
<td></td>
</tr>
<tr>
<td>Dist sc</td>
<td>20/25</td>
<td></td>
</tr>
</tbody>
</table>

Correction: Glasses

Visual Fields (Counting fingers):
- Left: Full
- Right: Full

Extraocular Movement:
- Right: Full
- Left: Full, Ortho

<table>
<thead>
<tr>
<th>Slit Lamp Exam</th>
<th>Right</th>
<th>Left</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lids/Lashes</td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>Conjunctiva/Sclera</td>
<td>White and quiet</td>
<td></td>
</tr>
<tr>
<td>Cornea</td>
<td>Clear</td>
<td></td>
</tr>
<tr>
<td>Anterior Chamber</td>
<td>Deep and quiet</td>
<td></td>
</tr>
<tr>
<td>Iris</td>
<td>Round and reactive</td>
<td></td>
</tr>
<tr>
<td>Lens</td>
<td>Centered posterior chamber intraocular lens, Dexycu residue on anterior optic</td>
<td></td>
</tr>
</tbody>
</table>

After 2.57 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

Two 1 mm clear corneal paracentesis incisions was created through which lidocaine with epinephrine was injected into the anterior chamber followed by viscoelastic (DiscoVisc®, Alcon Inc., Geneva, Switzerland) to stabilize the anterior chamber. The Tano diamond brush (Synergetics Inc., O’Fallon, MO, US) was used to carefully remove the residual Dexycu® material from the anterior aspect of the intraocular lens. This was accomplished without complication. The bimanual I/A was used to remove the remaining viscoelastic and Dexycu® debris from the anterior chamber. The corneal wound edges were hydrated with balanced salt solution on a cannula and the irrigation/aspiration handpiece was used to extract the remaining viscoelastic. Vigamox was injected into the anterior chamber at the end of the case. The wounds were inspected and were found to be watertight. Eye tension was adjusted to normal physiologic pressure. Topical Betadine, Brimonidine, and antibiotic drops were placed on the corneal surface.

The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.

Post-Procedural Clinical Examination at Day 0 (only note available):

OS: IOP 13.

Eye is well formed, paracenteses closed with no leaks, no corneal epithelial defects, 1+ cell, lens centered in bag.

Patient 7: 69 year old female with a relevant past medical history of central retinal vein occlusion with macular edema of the right eye, mucopurulent conjunctivitis of the right eye, posterior subcapsular polar age-related cataract of the right eye. This patient underwent phacoemulsification with intraocular lens implantation (MX60E, Bausch + Lomb, Laval, Canada) along with ab-interno canalomplasty, and Hydrus microstent insertion in the right eye. At a follow-up exam, 1.27 months post-op there was residue noted at the anterior surface of the right intraocular lens.
Residue Recognition Clinical Examination Day Right Eye:

After 11.2 months from the original operation, the patient consented and received a re-operation to try to remove the residue.

The following procedure was used:

A 1 mm clear corneal paracentesis incision was created superiorly through which lidocaine with epinephrine was injected into the anterior chamber. Viscoelastic (DiscoVisc®, Alcon Inc., Geneva, Switzerland) was used to stabilize the anterior chamber. An additional clear corneal paracentesis incision was made inferiorly. A Malyugin ring manipulator was used to inspect the edges of the intraocular lens. A Tano scrubber (Synergetics Inc., O’Fallon, MO, US) was used to gently polish the lens. Bimannual I/A was used to remove residual crystalline lens material from the anterior chamber. An Ahmed gonioprism was used to inspect the angles. The corneal wound edges were hydrated with balanced salt solution on a cannula and the irrigation/aspiration handpiece was used to extract the remaining viscoelastic. Then, 0.1 ml of Vigamox was injected into the anterior chamber. The wounds were inspected and were found to be watertight. Topical Betadine, Alphagan P, and antibiotic drops were placed on the corneal surface.

The patient tolerated the procedure well and was taken to the postoperative care unit in good condition. The patient will be discharged home with instructions for the use of topical antibiotics and anti-inflammatory drops, and the use of a metal shield at bedtime.

Post-Procedure Clinical Examination at 2 Weeks:

During 2020-2021, Dexycu® was billed 1,076 times in conjunction with cataract surgery at the Moran Eye Center. Of these patients, postoperative persistent residue was noted in 8 eyes of 7 patients. The median age of patients with residue was 66 years (range 53-79). Regarding surgery type, 3 eyes underwent routine phacoemulsification with IOL placement, 3 underwent combination procedures (e.g. ABIC™+Phaco+IOL), and 2 underwent complex phacoemulsification with IOL placement (e.g. complicated by synechialysis).
Patients received a 0.3 mL injection of lidocaine with epinephrine. The phacoemulsification was performed with 500 mL of Omidria® phenylephrine/ketorolac infusion (Omeros Corp., Seattle, WA). After lens removal, 0.1 mL of intracameral moxifloxacin was administered. The viscoelastic used in all 8 cases was DisCoVisc® (Alcon, Geneva, Switzerland). Six eyes received monofocal MX60E lenses (Bausch + Lomb, Bridgewater, NJ) and 2 eyes received toric lenses, the MX60UT125 and MX60UET350 (Bausch + Lomb, Bridgewater, NJ). A Dexycu® pellet was placed posterior to the iris in all patients per manufacturer specifications [5].

The average time from surgery to the discovery of the residue was 1.63 months (range 0.20-4.23). Of the 8 eyes with residue, 6 underwent the polishing procedure. The average time between the initial surgery and the polishing procedure was 4.71 months (range 1.90-11.20).This case series also describes utilizing a Tano diamond brush (Synergetics Inc., O’Fallon, MO, US) to delicately polishes the IOL without compromising the optical quality of the lens. The risks of an additional procedure must be evaluated in the context of benefit to the individual patient. In our cohort, two of the eyes did not undergo polishing because the risks of the additional procedure exceeded the potential benefit to the patient.

3. RESULTS AND DISCUSSION

The finding of persistent intraocular lens residue associated with the use of Dexycu® is not well studied and this case series is a significant addition to the medical literature.

Adhesion of foreign material to artificial intraocular lenses is a well-known phenomenon, with calcifications and silicone oil being identified as common culprits in various case studies [6-13]. An experimental study by Kageyama and Yaguchi showed that silicone oil was most likely to interact with silicone IOls and least likely to interact with hydrophobic acrylic lenses [9]. In the aqueous milieu of the posterior chamber, the hydrophobic Verisome® spherule of Dexycu® could promote the precipitation of residue on a hydrophobic IOL.

In this case series, the depositions observed involved the acrylic hydrophobic lenses B&L MX60 and its toric varieties.

The Bausch and Lomb intraocular lenses seem to be predisposed to a Dexycu® persistent opacification, however correlation does not equate with causation. The occurrence of opacification on an intraocular lens post-cataract surgery is not unique and has been well documented in the literature [14].

Further laboratory analysis with detailed sampling of the actual opacified matter is required to fully elucidate whether the molecular interaction between the MX60 hydrophobic lenses and Dexycu® is truly occurring as it appears. One should note that of the 8 surgeries, 5 surgeries involved additional procedures or ocular comorbidities. Several of the patients had diabetes mellitus type 2 predisposing them to metabolic syndromes [15-17]. Dexycu® is a steroid which is a diabetes risk factor. The unusual Dexycu® staining may be a symptom of underlying metabolic imbalance. Hence, further inquiry may determine whether there is a relationship between the presence of residue, the type of surgery, or pre-existing medical problems.

4. CONCLUSION

This article documents cases of persistent IOL residue with the use of Dexycu® in 8 eyes of 7 patients. Although all the patients who experienced this complication had MX60 lenses and its toric varieties, the relationship between the composition of the Dexycu® suspension and these lenses remains unclear. Further research is needed to characterize and better understand this phenomenon.

ETHICAL APPROVAL AND CONSENT

Approval to retrospectively review patient charts was obtained from the University of Utah IRB (#00146975). All patients consented to the publication of their case details and patient images were taken and shared with documented permission in their charts.

ACKNOWLEDGEMENTS

This investigation was supported by TRIAD, with funding in part from the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002538. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.

Supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.

The sponsor and funding organization had no role in the design or conduct of this research.

All authors attest that they meet the current ICMJE criteria for authorship.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

16. Libert DM, Nowacki AS, Natowicz MR. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: amino acid
and acylcarnitine levels change along a spectrum of metabolic wellness. PeerJ. 2018;6:e5410.


© 2022 Wallace et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/91015